SalioGen Therapeutics logo

SalioGen Therapeutics Funding & Investors

Cambridge, MA

SalioGen Therapeutics advances in curative genetic therapies using its Exact DNA Integration Technology (EDIT) platform, a mammal-derived genome engineering technology. It is focused on providing durable, safe, and affordable non-viral gene therapies to more patients with inherited diseases. Looking ahead, SalioGen will also explore the EDIT platformโ€™s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing to help an even broader population of patients in need.

saliogen.com

Total Amount Raised: $135,000,000

SalioGen Therapeutics Funding Rounds

  • Series B

    $115,000,000

    Series B Investors

    EPIQ Capital Group
    GordonMD Global Investments
    T. Rowe Price
    Cystic Fibrosis Foundation
    RD Fund
    Fidelity Investments
    D1 Capital Partners
    Symbiosis
  • Series A

    $20,000,000

    Series A Investors

    PBM Capital Group
Funding info provided by Diffbot.